Advertisement
Advertisement

Indicator

Free Access

Pay per View

Partial Free Access

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Venous Thrombotic Risk in Family Members of Unselected Individuals with Factor V Leiden

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2000: 83/6 (June) pp.802-970
Pages: 817-821

Venous Thrombotic Risk in Family Members of Unselected Individuals with Factor V Leiden

R. P. M. Lensen (1) , R. M. Bertina (2) , H. de Ronde (2) , J. P. Vandenbroucke (1) , F. R. Rosendaal (1),(2)
From the (1) Department of Clinical Epidemiology, Leiden University Medical Center, (2) Hemostasis and Thrombosis Research Center, Department of Haematology, Leiden University Medical Center, The Netherlands

Summary

The factor V Leiden mutation (FVL) leads to a seven-fold increased risk of venous thromboembolism (VTE). In thrombophilic families, 25% of carriers have experienced thrombosis before the age of 40 years. Aim of our study was to assess the association of FVL with VTE in first-degree family members of unselected symptomatic and asymptomatic carriers of FVL. We tested 197 relatives of consecutive thrombosis patients with FVL and 36 relatives of asymptomatic carriers on the presence of FVL and the occurrence of VTE. The incidence of VTE in relatives with FVL of symptomatic carriers was 0.34%/year. This was similar to the incidence in relatives with FVL of asymptomatic carriers. Kaplan Meier analysis in relatives of symptomatic propositi showed that at the age of 58 years, thrombosisfree survival was reduced to 75% in carriers and 93% in non-carriers (P < 0.05). Carriers of FVL had a three times higher thrombotic risk than non-carriers. In combination with environmental risk factors, FVL clearly adds to the risk of VTE. The thrombotic incidence rate in these unselected relatives with FVL, however, is considerably lower than was seen in carriers of thrombophilic families (1.7%/year). Therefore, special care should be paid to individuals with a positive family history of venous thrombosis while exposed to these risk factors.